Ubrelvy

(Ubrogepant)

Ubrelvy

Drug updated on 11/14/2023

Dosage FormTablet (oral: 50 mg, 100 mg)
Drug ClassCalcitonin gene-related peptide receptor antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the acute treatment of migraine with or without aura in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Ubrelvy (ubrogepant) Prescribing Information. 2021Allergan USA, Inc., Madison, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature.2023Cephalalgia
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.2022The Journal of Headache and Pain
Comparative efficacy and safety of rimegepant, ubrogepant and lasmiditan for acute treatment of migraine: a network meta-analysis. 2022Expert Review of Pharmacoeconomics & Outcomes Research
Safety evaluation of oral calcitonin-gene–related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis.2022European Journal of Clinical Pharmacology
Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies.2022Expert Opinion on Drug Safety
Ditans vs Gepants: a systematic review and indirect network meta-analysis for comparative analysis of efficacy and safety.2021Neurology India
Comparative efficacy of oral calcitonin-gene–related peptide antagonists for the treatment of acute migraine: updated meta-analysis.2021Clinical Drug Investigation
Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine. 2021Medicine
Comparison of new pharmacologic agents with triptans for treatment of migraine.2021JAMA
Acute treatments for migraine.2020ICER
Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials.2020CNS Drugs
Network meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine.2019Frontiers in Pharmacology